Nirrin Technologies Acquires IP and Hardware Assets of ASL Analytical, Inc.

Billerica, Mass., September 10, 2019, /PRNewswire/ — Nirrin Technologies, a developer of real-time, non-destructive bioprocess monitoring systems for the pharmaceutical and life sciences industries, today announced that it has acquired the intellectual property and hardware assets of ASL Analytical, Inc (“ASL”). The acquisition includes ASL’s provisional patent portfolio, existing patent applications, trademark portfolio, and other digital and hardware assets related to the company’s previous bioprocess monitoring product offerings.

The terms of the transaction were not disclosed.

“ASL was an innovator in the bioprocess monitoring space and created valuable intellectual property,” said Bryan Hassell, PhD, Cofounder and Chief Technology Officer of Nirrin Technologies. “This acquisition will help bolster Nirrin’s existing IP portfolio and further accelerate development as we prepare the launch of our own commercially available bioprocess monitoring systems.”

Founded in 2005 as a spin out of the University of Iowa, ASL developed chemical bioprocess monitors, including the RTBio™ 1000 CHO Bioprocess Monitor, for the automatic, real-time measurement of key chemicals during CHO cell culture bioprocesses.

“Biologics are fragile and chemically complex therapies. Having the ability to monitor processes inside a bioreactor in real-time, without interference, is critical for the advancement of therapeutics,” said Mark Arnold, Director for the Center for Biocatalysis and Bioprocessing at the University of Iowa and Acting Chief Scienfitic Officer and Founder of ASL. “NIRRIN Technologies’ team has already demonstrated significant advances in this field and we’re delighted to see ASL’s assets contribute to Nirrin’s continued success.

###

About Nirrin Technologies
Nirrin Technologies develops disruptive products to deliver non-destructive, real-time, in-process monitoring of aqueous solutions that can enable improved process control, faster process development, and adaptive manufacturing for the biopharma and life science industries. NIrrin leverages best-in-class NIR technology, innovative chemometric/analytical methods, and application-specific knowledge to deliver effective, robust, and simple-to-use solutions that are cost-effective, flexible, and scalable to address dynamic customer needs. For more information, please visit: https://www.nirrin.tech.